Long-Term Functional Results of Ewing Tumor Treatment

Long-Term Functional Results of Ewing Tumor Treatment - Long-Term Functional Results of Ewing Tumor Treatment

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36450

Enrollment

Registered

2011-07-29

Start date

2011-08-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewing tumor skeletal malignancy

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: This is a cohort study that will include all patients with histologically confirmed Ewing tumor of the previous CESS 81, CESS 86, EICESS 92 and ongoing EURO-E.W.I.N.G. 99 (expected closing date end of 2008) of the German Society for Pediatric Oncology and Hematology (GPOH). Additionally, all Ewing tumor patients will be included who have been registered as follow-up patients to the Ewing tumor trail center in Münster from 150 participating institutions in Germany and about 30 additional centers in the neighboring countries. (Among them the AMC)

Exclusion criteria

Exclusion criteria: Patients with any kind of paralysis will be excluded from the functional measurement (

Design outcomes

Primary

Measure	Time frame
The results will be used to identify those changes in functional capacity that likely result in long-term physical, intellectual, or psychological problems, and to develop strategies for reducing long-term effects of different therapeutic approaches.	—

Secondary

Measure	Time frame
The secondary objective is to establish and upgrade a unique data pool of 2700 Ewing patients that allows to perform differential analyses of diagnostic, treatment, and follow-up data from childhood cancer patients covering a period of 30 years. Prognostic factors for long-term survival will be obtained. Risk ratios for survival between treatment options will be computed to combine long-term functional and survival outcome results. Guidelines for future treatment practice and long-term follow-up will be provided.	—

Measure

Time frame

The secondary objective is to establish and upgrade a unique data pool of 2700 Ewing patients that allows to perform differential analyses of diagnostic, treatment, and follow-up data from childhood cancer patients covering a period of 30 years. Prognostic factors for long-term survival will be obtained. Risk ratios for survival between treatment options will be computed to combine long-term functional and survival outcome results. Guidelines for future treatment practice and long-term follow-up will be provided.

—

Countries

Netherlands

Outcome results